Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone without significantly affecting cortisol, prolactin, or aldosterone levels. This selectivity makes it one of the cleanest growth hormone peptides available. It is commonly used in anti-aging and body composition protocols, often combined with CJC-1295 for sustained GH elevation.
FormBlends Peptide Context
Reviewed May 14, 2026Read Ipamorelin peptide guide with the practical follow-up in mind. If the topic involves peptide therapy, the next useful step is usually to verify evidence strength, access rules, pharmacy pathway, total cost, and the personal safety details that only a clinician can review.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
Ipamorelin authority snapshot
Ipamorelin is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Meaningful evidence with limits
Regulatory reality
Reinstated for compounding (Feb 2026)
Safety screen
Mild headache, Water retention during initial weeks, Injection site irritation should be reviewed in context.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for Ipamorelin?
Ipamorelin should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- Ipamorelin
- Category
- Growth Hormone
- Evidence
- Meaningful evidence with limits
- FDA status
- Not FDA approved
Step 1
Check evidence level
Ipamorelin has been tested in several human trials, most notably a Phase 2 study in post-surgical patients (N=161) that showed it safely accelerated GI recovery. It's one of the better-studied growth hormone secretagogues, with consistent safety data across trials. The human evidence is real but limited to specific clinical contexts.
Review evidenceStep 2
Screen safety context
Mild headache, Water retention during initial weeks, Injection site irritation should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If this is research-only or not directly offered, compare clinic and provider routes before taking action.
Compare clinicsGrowth hormone axis hub
CJC-1295 and ipamorelin pages should explain the GH-axis decision
CJC-1295 and ipamorelin are not best handled as generic performance peptides. The useful read is whether the goal involves sleep, body composition, recovery, or growth hormone signaling, and whether labs, contraindications, and expectations make the pathway reasonable.
Decision question for Ipamorelin
Is the reader trying to optimize recovery, or are there symptoms that need endocrine evaluation first?
Peptide evidence layer
Evidence read
The strongest content should explain GHRH analog signaling, ghrelin receptor activity, IGF-1 context, why pulses matter, and why outcomes are not the same as direct growth hormone treatment.
Safety watch
A careful screen should consider diabetes risk, edema, carpal tunnel symptoms, cancer history, sleep apnea, headaches, elevated IGF-1, and whether symptoms point to another endocrine condition.
Conversion fit
The conversion path should route to provider review with lab context, sleep history, body-composition goals, and medication history instead of promising fast performance outcomes.
Last updated: April 3, 2026
Typical Dosage
200-300 mcg injected subcutaneously, 2-3 times daily. Most commonly dosed at bedtime or pre-workout.
Administration
Subcutaneous injection
Typical Cost
$150-300/month
FDA Status
Not FDA Approved
Half-Life
Approximately 2 hours
Onset of Action
GH levels peak within 30-45 minutes of injection. Body composition changes require 3-6 months of consistent use.
Bioavailability
Subcutaneous injection provides consistent absorption. Not orally bioavailable.
About Ipamorelin
Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a molecular weight of 711.85 Da. Its CAS number is 170851-70-4. It belongs to the growth hormone secretagogue (GHS) class, meaning it stimulates the pituitary gland to release growth hormone.
What sets ipamorelin apart from other GH secretagogues is its selectivity. A 1999 study in the European Journal of Endocrinology (PMID: 10601960) showed that ipamorelin stimulates GH release without affecting cortisol, ACTH, prolactin, or gonadotropin levels. That matters because older secretagogues like GHRP-6 and GHRP-2 cause cortisol spikes and intense hunger (from ghrelin receptor activation in the gut). Ipamorelin triggers GH release through the same ghrelin receptor but with much higher selectivity for pituitary somatotrophs.
The most significant human trial was a Phase 2 study published in the Journal of Clinical Pharmacology in 2007 (PMID: 17218486). Researchers tested ipamorelin in 161 patients recovering from abdominal surgery to see if it could speed up the return of normal bowel function. The results showed faster GI recovery with a clean safety profile. No significant adverse events were attributed to ipamorelin. While the trial wasn't designed to measure body composition effects, it confirmed that repeated dosing in humans is well-tolerated.
Ipamorelin works by binding to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. When activated, this receptor triggers a signaling cascade that releases stored growth hormone into the bloodstream. The key difference from direct GH injection is that ipamorelin preserves the body's natural feedback loops. The pituitary still responds to somatostatin (the GH-inhibiting hormone), so you don't get the sustained supraphysiological GH levels that cause problems with exogenous GH.
The peptide has a half-life of roughly 2 hours, which is longer than GHRP-6 (about 30 minutes) but shorter than CJC-1295 DAC (days). Most practitioners recommend 200-300 mcg injected subcutaneously 2-3 times daily, with the most important dose given before bed to amplify the natural nocturnal GH surge.
Ipamorelin is almost always used in combination with a GHRH analog, typically CJC-1295 (either with or without the DAC modification). The reasoning is straightforward: ipamorelin amplifies GH release by activating the ghrelin pathway, while CJC-1295 activates the GHRH pathway. Using both at once produces a synergistic GH pulse that's stronger than either compound alone.
Lyophilized ipamorelin should be stored at -20C before reconstitution. Add bacteriostatic water slowly against the vial wall and swirl gently. Don't shake. Store reconstituted vials at 2-8C and use within 28 days.
How Ipamorelin Works
Ipamorelin acts as a ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHS-R) in the pituitary gland. Unlike other GH secretagogues such as GHRP-6 or GHRP-2, ipamorelin does not significantly stimulate appetite or raise cortisol and prolactin. It triggers GH release in a dose-dependent manner that respects the body's natural somatostatin feedback, preventing excessive GH spikes.
Receptor targets:
Benefits
- Stimulates growth hormone release without cortisol elevation
- Improves body composition by increasing lean mass and reducing fat
- Does not cause significant hunger increase like other GH peptides
- Supports deeper and more restorative sleep
- Enhances collagen production and skin quality
- Improves bone density over long-term use
- Well tolerated with minimal side effects compared to other secretagogues
What Does the Research Say?
Ipamorelin has been tested in several human trials, most notably a Phase 2 study in post-surgical patients (N=161) that showed it safely accelerated GI recovery. It's one of the better-studied growth hormone secretagogues, with consistent safety data across trials. The human evidence is real but limited to specific clinical contexts.
Safety and efficacy of ipamorelin for postoperative ileus
Journal of Clinical Pharmacology, 2007 · DOI · PubMed
Phase 2 trial in 161 post-surgical patients showed ipamorelin accelerated GI recovery with a favorable safety profile
PubMed evidence trail
Research sources used to frame this page
For Ipamorelin, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Potential Side Effects
- Mild headache
- Water retention during initial weeks
- Injection site irritation
- Occasional lightheadedness
- Tingling or numbness in extremities
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Somatostatin analogs (octreotide, lanreotide) | Directly blocks the GH release triggered by ipamorelin. These work in opposite directions. | major |
| Insulin | GH and insulin have opposing metabolic effects. High-dose GH secretion can reduce insulin sensitivity. Monitor blood glucose if using both. | moderate |
Who Is Ipamorelin For?
Women
No sex-specific contraindications. Women tend to have higher baseline GH levels, so the relative increase may differ. Often combined with HRT in perimenopausal women.
Adults Over 50
Good candidate for age-related GH decline. The selectivity of ipamorelin (no cortisol or prolactin spikes) makes it particularly suitable for older adults who may be more sensitive to hormonal disruption.
Athletes
Banned by WADA under the growth hormone secretagogue category (S2). Popular in bodybuilding for its clean GH release profile without the hunger spikes of GHRP-6.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Reinstated for compounding (Feb 2026)
Ipamorelin was one of the peptides affected by FDA restrictions in late 2023 but was reinstated for compounding in the February 2026 HHS reclassification.
Last verified: 2026-04-06
Stacking Options
Ipamorelin is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Find a Ipamorelin Clinic Near You
Browse peptide therapy clinics in your area that offer ipamorelin treatments.
Find Peptide Clinics